

Summary of Changes

**HRG4+ 2021/22 Local Payment Grouper
from:**

HRG4+ 2020/21 Local Payment Grouper v2 (COVID-19)

Published March 2021



**Information and technology
for better health and care**

Contents

Grouper Release and HRG Design Summary, 2020 and 2021	3
Summary of Changes	7
Changes to the HRG4+ Grouper	8
<hr/>	
Grouper Input Changes	8
Grouper Output Changes	8
Grouper Software Changes	8
Grouper Algorithm Changes	8
HRG Design Changes	8
Update of base design	8
Change to the number of HRGs	9
Changes introduced in the HRG4+ 2021/22 Local Payment Grouper	9
Accommodation of CDS Updates - Main Speciality and Treatment Function Codes	11
Changes to Best Practice Flags	12
<hr/>	
Appendix A: HRG Distribution by Subchapter	13
The Documentation Suite	23

Grouper Release and HRG Design Summary, 2020 and 2021

The following section summarises the background to the release of the HRG4+ 2021/22 Local Payment Grouper. It provides a recap of updates to the HRG4+ 2020/21 Local Payment Grouper (Version 1), which culminated in the release of the HRG4+ 2020/21 Local Payment Grouper Version 2 (COVID-19).

The HRG4+ 2020/21 Local Payment Grouper (now referred to as Version 1) was released in March 2020, incorporating OPCS-4.9 updates, effective for use by the Service from 1 April 2020.

In response to the global pandemic and following updated guidance from the World Health Organisation (WHO), the Clinical Classifications Service (CCS) updated the 5th Edition of ICD-10 (International Statistical Classification of Diseases and Related Health Problems) to reclassify 2 “Emergency Use” codes, specifically for use in relation to COVID-19 infection. These are:

- **U07.1 COVID-19, virus identified**
Must only be assigned for laboratory confirmed cases of COVID-19 (i.e. positive test result)
- **U07.2 COVID-19, virus not identified**
Is used when COVID-19 is diagnosed clinically or epidemiologically but laboratory testing is inconclusive or not available

These were incorporated in an updated design and resulted in the release of the HRG4+ 2020/21 Local Payment Grouper Version 2 (COVID-19) in July 2020.

The updated design introduced a new Subchapter, **DX COVID-19 Infection**, containing 6 new HRGs for patients of all ages with a primary diagnosis of either test positive or clinically-determined COVID-19, and no significant procedure(s).

The updated design treats **U07.2 COVID-19, virus not identified** as clinically identical to **U07.1 COVID-19, virus identified**, mapping these diagnoses codes, when recorded as a primary diagnosis, to the new **DX COVID-19 Infection** subchapter (where no significant procedures have been undertaken). Thus **U07.1 COVID-19, virus identified, and U07.2 COVID-19, virus not identified** were included on the same subchapter-specific complications and comorbidities lists, and both map to Programme Budgeting Category **PBC0211X Problems of the Respiratory System**.

In line with established grouper delivery cycles, the HRG4+ 2020/21 Local Payment Grouper Version 2 (COVID-19) was superseded by an updated design in the HRG4+ 2021/22 Consultation Grouper, released in February 2021. The HRG4+ 2021/22 Local Payment Grouper includes further design updates, and is available for use from 1 April 2021.

Changes implemented in the HRG4+ 2021/22 Consultation Grouper

In November 2020, the coding guidance issued by the WHO with regard to the recording of COVID-19 infection-related disorders was updated. In response, the CCS updated the underlying ICD-10 classification. The HRG design was therefore amended to reflect changes in national coding guidance relating to COVID-19 infection-related disorders.

The following 3 Emergency Use ICD-10 code descriptions were updated:

- ***U07.3 Personal history of COVID-19***
- ***U07.4 Post COVID-19 condition***
- ***U07.5 Multisystem inflammatory syndrome associated with COVID-19***

U07.3 Personal history of COVID-19

This code is expected to be used in a secondary diagnosis position to record an earlier episode of COVID-19, as documented in the notes as either confirmed or probable, influencing the person's health status, and where the person is no longer suffering from COVID-19. This ICD-10 code is not to be used in the primary position.

This code was remapped from HRG root **WH15 Special Screening, Examinations or Other Genetic Disorders** (adult patients) and HRG root **PX57 Paediatric, Examination, Follow-up, Special Screening or Other Admissions** (child patients) to **UZ01Z Data Invalid for Grouping** as, according to national clinical coding standards, this code is not permitted to be used as a primary diagnosis, as per most similar code **Z86.1 Personal history of infectious and parasitic diseases**. When recorded as a primary diagnosis it will generate error code **UZ01 Invalid Primary Diagnosis: 1. Primary Diagnosis doesn't exist or 2. Primary Diagnosis Blank or 3. Diagnosis can't be used at primary position**.

This code was not added to any complications and comorbidity lists as per clinical advice. This code was remapped to base PBC category, **PBC0201X Infectious Diseases**.

U07.4 Post COVID-19 condition

This code is expected to be recorded secondary to the condition that is post COVID-19. This code allows the establishment of a link with COVID-19 where it is documented. This ICD-10 code is not to be used where the patient is still presenting with a COVID-19 infection.

This code was not added to any complications and comorbidity lists as per clinical advice. This code remained mapped to base PBC **PBC0223X Other**.

U07.5 Multisystem inflammatory syndrome associated with COVID-19

This ICD-10 code is expected to be recorded in a secondary position to the active COVID-19 diagnosis codes for patients that present with, or develop this condition.

This code was remapped from HRG root **WH15 Special Screening, Examinations or Other Genetic Disorders** to HRG root **WJ06 Sepsis** in adults, and HRG roots **PW16 Paediatric Major Infections** in children and **PM45 Paediatric Febrile Neutropenia with Malignancy** in children with an additional diagnosis of cancer and agranulocytosis. This matched the mapping of the ICD-10 code in use for this disorder before the introduction of this emergency use code; **R65.0 Systemic Inflammatory Response Syndrome of infectious origin without organ failure**.

As per **R65.0 Systemic Inflammatory Response Syndrome of infectious origin without organ failure** this code was added to the paediatric, burns and adult infectious diseases complications and co-morbidities lists, and the **DX_Major** (major manifestations of COVID-19) list. This code was remapped to base PBC category, **PBC0201X Infectious Diseases**.

The HRG4+ 2021/22 Consultation Grouper was updated to reflect the hitherto unprecedented in-year changes in national coding guidance for the above ICD-10 codes. Whilst historically this grouper release has been used to support the NHS England and Improvement Section 118 formal Consultation process, that was not the case in 2021, as the Consultation process had not yet occurred, though the publication of the HRG4+ 2021/22 Consultation Grouper received Pricing policy approval. This release does not, however, pre-empt anything to be included in the policy Consultation for the 2021/22 tariff, which may be published in due course.

Changes introduced in the HRG4+ 2021/22 Local Payment Grouper

In February 2021 updated coding guidance was issued by the WHO relating to a further 2 Emergency Use ICD-10 codes, to support vaccination against COVID-19. As a result, the underlying ICD-10 classification has again been updated by the CCS, and the HRG design has necessarily been amended, for use from 1 April 2021, to reflect changes in national coding guidance relating to vaccination against COVID-19.

The following ICD-10 code descriptions have been updated:

- **U07.6 Need for immunization against COVID-19**
- **U07.7 COVID-19 vaccines causing adverse effects in therapeutic use**

U07.6 Need for immunization against COVID-19

This code is expected to be used in the same way as codes from category **Z24 Need for immunization against certain single viral diseases** and must be assigned in accordance with *DCS.XXI.3: Persons with potential health hazards related to communicable diseases (Z20–Z29)*. This code is expected to be used as a primary diagnosis when a patient has been admitted to receive their COVID-19 vaccination. It may also be used as a secondary diagnosis to indicate that a patient has received their COVID-19 vaccination whilst admitted.

U07.7 COVID-19 vaccines causing adverse effects in therapeutic use

This code is expected to be used in the same way as codes from category **Y59 Other and unspecified vaccines and biological substances** and must be assigned in accordance with *DCS.XX.7: Drugs, medicaments and biological substances causing adverse effects in therapeutic use (Y40-Y59)*. This code is not permitted to be recorded as a primary diagnosis.

The HRG4+ 2021/22 Local Payment Grouper updated design and release is similarly extraordinary in that, as of this grouper release, the 2021/22 Section 118 formal Consultation process by NHS England and Improvement has not yet been published. The release of this product, however, has Pricing policy consent, and is necessary to ensure that changes to national coding guidance in relation to vaccination against COVID-19, and changes to main specialty codes (MSC) and treatment function codes (TFC), effective from 1 April 2021, can be appropriately recognised when processing and understanding healthcare activity data.

High-level details of HRG design and grouper changes are outlined below. Further details of design changes can be found in the Chapter Summaries and supporting documentation that accompanies this grouper release.

Comprehensive national coding guidance can be found here:

https://hscic.kahootz.com/connect.ti/t_c_home/view?objectId=19099248#19099248

Summary of Changes

The purpose of this summary is to provide an overview of the main changes between the HRG4+ 2021/22 Local Payment Grouper and the HRG4+ 2020/21 Local Payment Grouper Version 2 (COVID-19).

Changes are broken down by:

- **Grouper Input Changes**
- **Grouper Output Changes**
- **Grouper Software Changes**
- **Grouper Algorithm Changes**
- **HRG Design Changes**

This document also includes a high-level description of design changes by subchapter as well as HRG distribution by subchapter, in Appendix A.

This high-level summary document is intended to be used to form the basis of further analysis and investigation rather than as a comprehensive list of all differences between grouper releases. Further HRG4+ supporting documentation is available from the National Casemix Office website:

<https://digital.nhs.uk/services/national-casemix-office/downloads-groupers-and-tools/payment-groupers>.

Changes to the HRG4+ Grouper

The following changes have been made:

Grouper Input Changes

Changes implemented in the HRG4+ 2021/22 Consultation Grouper

There were no changes to the inputs of the grouper in this release.

Changes implemented in the HRG4+ 2021/22 Local Payment Grouper

There has been one change applied to the Paediatric and Neonatal Critical Care datasets in Single Spell in the HRG4+ 2021/22 Local Payment Grouper input.

In the HRG4+ 2021/22 Consultation Grouper, the number of episodes that could be opened in a single spell for both the Paediatric and Neonatal Critical Care datasets was 87. In the HRG4+ 2021/22 Local Payment Grouper, 99 episodes can be opened in a single spell.

This change has been implemented to enable the demonstration of the 90-day ventilation logic in the Paediatric Critical Care design, whereby a different HRG is derived when there are more than 90 days of consecutive ventilation support.

Grouper Output Changes

There are no changes to the outputs of the grouper in either the HRG4+ 2021/22 Consultation Grouper or the HRG4+ 2021/22 Local Payment Grouper.

Grouper Software Changes

There are no changes to the software of the grouper in either the HRG4+ 2021/22 Consultation Grouper or the HRG4+ 2021/22 Local Payment Grouper.

Grouper Algorithm Changes

There are no changes to the algorithm of the grouper in either the HRG4+ 2021/22 Consultation Grouper or the HRG4+ 2021/22 Local Payment Grouper.

HRG Design Changes

Update of base design

The design base for the HRG4+ 2021/22 Local Payment Grouper is the HRG4+ 2021/22 Consultation Grouper. The latter is based on the 2020/21 Local Payment Grouper Version 2 (COVID-19), which is itself based on the HRG4+ 2016/17 Reference Costs design, updated to include both the 4.8 and 4.9 updates to the

OPCS Classification of Interventions and Procedures Version 4, which came into effect in April 2017 and April 2020, respectively.

Change to the number of HRGs

There has been no change to the number of HRGs in the HRG4+ 2021/22 Local Payment Grouper. The number of HRGs in this grouper is the same as in both the HRG4+ 2021/22 Consultation Grouper and the HRG4+ 2020/21 Local Payment Grouper Version 2 (COVID-19): 2,838.

Changes introduced in the HRG4+ 2021/22 Local Payment Grouper

The HRG design has been updated to accommodate the use of Emergency Use ICD-10 codes in line with WHO requirements.

The following Emergency Use ICD-10 codes have been updated:

- ***U07.6 Need for immunization against COVID-19***
- ***U07.7 COVID-19 vaccines causing adverse effects in therapeutic use***

Following the changes in national coding guidance affecting these 2 codes in February 2021, the codes have been remapped to ensure that the diagnoses classified by these codes are appropriately accommodated within the HRG design.

U07.6 Need for immunization against COVID-19

This code has been remapped from HRG root **WH15 Special Screening, Examinations or Other Genetic Disorders** to **WH19 Potential Health Hazard Related to Communicable Disease** for adult patients and retains mapping to HRG root **PX57 Paediatric, Examination, Follow-up, Special Screening or Other Admissions** for children. This matches the mapping of the ICD-10 code in use for this disorder before the introduction of this emergency use code; **Z25.8 Need for immunization against other specified single viral diseases**.

This code has not been added to any complications and comorbidity lists as per clinical advice. This code has been remapped to base PBC category **PBC0221X Healthy Individuals**.

U07.7 COVID-19 vaccines causing adverse effects in therapeutic use

This code has been remapped from HRG root **WH15 Special Screening, Examinations or Other Genetic Disorders** in adults and **PX57 Paediatric, Examination, Follow-up, Special Screening or Other Admissions** in children to **UZ01 Data Invalid for Grouping** as, according to national clinical coding standards, this code is not permitted to be used as a primary diagnosis, as per most similar code **Y59.0 Viral vaccines**. When recorded as a primary diagnosis, it will generate error code **UZ01 Invalid Primary Diagnosis: 1. Primary Diagnosis doesn't exist**

or 2. Primary Diagnosis Blank or 3. Diagnosis can't be used at primary position.

This code has not been added to any complications and comorbidity lists as per clinical advice. This code has been remapped to base PBC category **PBC02U2 Unclassified**

The grouper has therefore been updated to reflect changes in national coding guidance relating to vaccination against COVID-19.

Accommodation of CDS Updates - Main Speciality and Treatment Function Codes

New MSCs and TFCs were introduced from April 2020 as part of the update to the DCB0028: Treatment Function and Main Specialty Standard. As the use of these codes became mandatory from April 2021, these codes have been added to the MSC and TFC lists used for validation within the grouper.

The three new MSC codes are:

- 107 Vascular Surgery**
- 200 Aviation and Space Medicine**
- 317 Allergy**

The 25 new TFC codes are:

- 109 Bariatric Surgery Service**
- 111 Orthopaedic Service**
- 113 Endocrine Surgery Service**
- 115 Trauma Surgery Service**
- 145 Oral and Maxillofacial Surgery Service**
- 200 Aviation and Space Medicine Service**
- 230 Paediatric Clinical Pharmacology Service**
- 240 Paediatric Palliative Medicine Service**
- 250 Paediatric Hepatology Service**
- 270 Paediatric Emergency Medicine Service**
- 326 Acute Internal Medicine Service**
- 333 Rare Disease Service**
- 335 Inherited Metabolic Medicine Service**
- 347 Sleep Medicine Service**
- 348 Post COVID-19 Syndrome Service**
- 431 Orthogeriatric Medicine Service**
- 451 Special Care Dentistry Service**
- 461 Ophthalmic and Vision Science Service**
- 504 Community Sexual and Reproductive Health Service**
- 505 Fetal Medicine Service**
- 670 Urological Physiology Service**
- 673 Vascular Physiology Service**
- 675 Cardiac Physiology Service**
- 677 Gastrointestinal Physiology Service**
- 730 Neuropsychiatry Service**

The three new MSC codes have also been added to the Core 6 grouping logic to ensure that these codes can be used to generate the appropriate default outpatient attendance HRGs. Core 6 logic has historically been used to determine the “alternate attendance HRG” (for Local Payment Grouper products), which represents the attendance HRG (WF01A/B or WF02A/B) paid when the core (non WF*) outpatient HRG does not have a mandatory tariff price.

In addition, the labels of many existing MSC and TFC codes have been updated to match changes made as part of this update.

Further information on the DCB0028: Treatment Function and Main Specialty Standard can be found here: [DCB0028: Treatment Function and Main Specialty Standard – NHS Digital](#).

The data dictionary has also been updated to reflect these changes, with further details found here: [Main Specialty and Treatment Function Codes Table \(datadictionary.nhs.uk\)](#).

Changes to Best Practice Flags

There are no changes to the underlying design of the Best Practice Flags in either the HRG4+ 2021/22 Consultation Grouper or the HRG4+ 2021/22 Local Payment Grouper.

Appendix A: HRG Distribution by Subchapter

The following table includes a high-level description of design changes implemented in the HRG4+ 2021/22 Consultation Grouper and those implemented in the HRG4+ 2021/22 Local Payment Grouper, by subchapter, when compared to the HRG4+ 2020/21 Local Payment Grouper Version 2 (COVID-19).

Changes made to the design of one HRG subchapter may have a significant impact on HRG grouping within other subchapters. This is especially true where changes have been made to procedure hierarchy values. Likewise, global design changes may impact HRG grouping within a subchapter even where no changes have been made to the subchapter itself.

Subchapter	LP21/22	LP20/21 v2 (July 2020)	Comment
AA Nervous System Procedures and Disorders	101	101	No change to HRG number or labels
AB Pain Management	13	13	No change to HRG number or labels
BZ Eyes and Periorbita Procedures and Disorders	94	94	No change to HRG number or labels
CA Ear, Nose, Mouth, Throat and Neck Procedures	120	120	No change to HRG number or labels
CB Ear, Nose, Mouth, Throat and Neck Disorders	12	12	No change to HRG number or labels
CD Dental and Orthodontic Procedures	23	23	No change to HRG number or labels
DX COVID-19 Infection	6	6	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the major manifestations list, DX_Major
DZ Respiratory System Procedures and Disorders	176	176	No change to HRG number or labels

Subchapter	LP21/22	LP20/21 v2 (July 2020)	Comment
EB Cardiac Disorders	48	48	No change to HRG number or labels
EC Open and Interventional Procedures for Congenital Heart Disease	21	21	No change to HRG number or labels
ED Open Cardiac Procedures for Acquired Conditions	48	48	No change to HRG number or labels
EY Interventional Cardiology for Acquired Conditions	65	65	No change to HRG number or labels
FD Digestive System Disorders	54	54	No change to HRG number or labels
FE Digestive System Endoscopic Procedures	37	37	No change to HRG number or labels
FF Digestive System Open and Laparoscopic Procedures	112	112	No change to HRG number or labels
GA Hepatobiliary and Pancreatic System Open and Laparoscopic Procedures	27	27	No change to HRG number or labels
GB Hepatobiliary and Pancreatic System Endoscopic Procedures	14	14	No change to HRG number or labels
GC Hepatobiliary and Pancreatic System Disorders	24	24	No change to HRG number or labels
HC Spinal Procedures and Disorders	74	74	No change to HRG number or labels

Subchapter	LP21/22	LP20/21 v2 (July 2020)	Comment
HD Musculoskeletal and Rheumatological Disorders	35	35	No change to HRG number or labels
HE Orthopaedic Disorders	84	84	No change to HRG number or labels
HN Orthopaedic Non-Trauma Procedures	111	111	No change to HRG number or labels
HT Orthopaedic Trauma Procedures	87	87	No change to HRG number or labels
JA Breast Procedures and Disorders	35	35	No change to HRG number or labels
JB Burns Procedures and Disorders	38	38	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: <i>U07.5 Multisystem inflammatory syndrome associated with COVID-19</i> was added to the complications and comorbidities list for this subchapter, JB_CC
JC Skin Procedures	12	12	No change to HRG number or labels
JD Skin Disorders	10	10	No change to HRG number or labels
KA Endocrine System Disorders	18	18	No change to HRG number or labels
KB Diabetic Medicine	12	12	No change to HRG number or labels
KC Metabolic Disorders	9	9	No change to HRG number or labels
LA Renal Procedures and Disorders	48	48	No change to HRG number or labels
LB Urological and Male Reproductive System Procedures and Disorders	149	149	No change to HRG number or labels

Subchapter	LP21/22	LP20/21 v2 (July 2020)	Comment
LD Renal Dialysis for Chronic Kidney Disease	26	26	No change to HRG number or labels
LE Renal Dialysis for Acute Kidney Injury	4	4	No change to HRG number or labels
MA Female Reproductive System Procedures	48	48	No change to HRG number or labels
MB Female Reproductive System Disorders	17	17	No change to HRG number or labels
MC Assisted Reproduction Medicine	11	11	No change to HRG number or labels
NZ Obstetric Medicine	55	55	No change to HRG number or labels
PB Neonatal Disorders	20	20	<u>Changes implemented in the HRG4+ 2021/22 Consultation Grouper:</u> U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PB_CC
PC Paediatric Ear Nose and Throat Disorders	4	4	<u>Changes implemented in the HRG4+ 2021/22 Consultation Grouper:</u> U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PC_CC
PD Paediatric Respiratory Disorders	24	24	<u>Changes implemented in the HRG4+ 2021/22 Consultation Grouper:</u> U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PD_CC
PE Paediatric Cardiology Disorders	12	12	<u>Changes implemented in the HRG4+ 2021/22 Consultation Grouper:</u> U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PE_CC

Subchapter	LP21/22	LP20/21 v2 (July 2020)	Comment
PF Paediatric Gastroenterology Disorders	17	17	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PF_CC
PG Paediatric Hepatobiliary Disorders	3	3	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PG_CC
PH Paediatric Rheumatology Disorders	4	4	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PH_CC
PJ Paediatric Dermatology Disorders	7	7	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PJ_CC
PK Paediatric Diabetology, Endocrinology and Metabolic Disorders	11	11	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PK_CC
PL Paediatric Renal Disorders	10	10	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PL_CC
PM Paediatric Haematological-Oncology Disorders	14	14	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was remapped from HRG root PX57 Paediatric, Examination, Follow-up, Special Screening or Other Admissions to PW16 Paediatric Major Infections for patients 18 years and under and to PM45 Paediatric Febrile Neutropenia with Malignancy for patients 18 and under where an additional diagnosis of cancer and agranulocytosis is recorded U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PM_CC , and the lists associated with the generation of HRG root PM45 Paediatric Febrile Neutropenia with Malignancy, PM_Canc_Inf_Neut and PM_Infection

Subchapter	LP21/22	LP20/21 v2 (July 2020)	Comment
PN Paediatric Non-Malignant Haematological Disorders	9	9	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PN_CC
PP Paediatric Ophthalmic Disorders	2	2	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PP_CC
PQ Paediatric Immune System Disorders	2	2	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PQ_CC
PR Paediatric Nervous System Disorders	22	22	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PR_CC
PT Paediatric Mental Health Disorders	4	4	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PT_CC
PV Paediatric Trauma Medicine	7	7	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PV_CC
PW Paediatric Infectious Diseases	15	15	Changes implemented in the HRG4+ 2021/22 Consultation Grouper: U07.5 Multisystem inflammatory syndrome associated with COVID-19 was remapped from HRG root PX57 Paediatric, Examination, Follow-up, Special Screening or Other Admissions to PW16 Paediatric Major Infections for patients 18 years and under and to PM45 Paediatric Febrile Neutropenia with Malignancy for patients 18 and under where an additional diagnosis of cancer and agranulocytosis is recorded U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PW_CC

Subchapter	LP21/22	LP20/21 v2 (July 2020)	Comment
PX Paediatric Medicine	46	46	<p><u>Changes implemented in the HRG4+ 2021/22 Consultation Grouper:</u></p> <p>U07.3 Personal history of COVID-19 was remapped for patients 18 years and under from HRG root PX57 Paediatric, Examination, Follow-up, Special Screening or Other Admissions to UZ01Z Data Invalid for Grouping as this code is not permitted to be used as a primary diagnosis</p> <p>U07.5 Multisystem inflammatory syndrome associated with COVID-19 was remapped from HRG root PX57 Paediatric, Examination, Follow-up, Special Screening or Other Admissions to PW16 Paediatric Major Infections for patients 18 years and under and to PM45 Paediatric Febrile Neutropenia with Malignancy for patients 18 and under where an additional diagnosis of cancer and agranulocytosis is recorded</p> <p>U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, PX_CC</p> <p><u>Changes implemented in the HRG4+ 2021/22 Local Payment Grouper:</u></p> <p>U07.7 COVID-19 vaccines causing adverse effects in therapeutic use has been remapped for patients aged 18 years and under from HRG root PX57 Paediatric, Examination, Follow-up, Special Screening or Other Admissions to UZ01 Data Invalid for Grouping as, according to national clinical coding standards, this code is not permitted to be used as a primary diagnosis</p>
RD Diagnostic Imaging Procedures	47	47	No change to HRG number or labels
RN Nuclear Medicine Procedures	69	69	No change to HRG number or labels
SA Haematological Procedures and Disorders	104	104	No change to HRG number or labels
SB Chemotherapy	18	18	No change to HRG number or labels
SC Radiotherapy	30	30	No change to HRG number or labels
SD Specialist Palliative Care	10	10	No change to HRG number or labels

Subchapter	LP21/22	LP20/21 v2 (July 2020)	Comment
UZ Undefined Groups	1	1	<p><u>Changes implemented in the HRG4+ 2021/22 Consultation Grouper:</u></p> <p>U07.3 Personal history of COVID-19 was remapped from HRG root WH15 Special Screening, Examinations or Other Genetic Disorders (adult patients) and HRG root PX57 Paediatric, Examination, Follow-up, Special Screening or Other Admissions (child patients) to UZ01 Data Invalid for Grouping as this code is not permitted to be used as a primary diagnosis</p> <p><u>Changes implemented in the HRG4+ 2021/22 Local Payment Grouper:</u></p> <p>U07.7 COVID-19 vaccines causing adverse effects in therapeutic use has been remapped from HRG root WH15 Special Screening, Examinations or Other Genetic Disorders (adult patients) and HRG root PX57 Paediatric, Examination, Follow-up, Special Screening or Other Admissions (child patients) to UZ01Z Data Invalid for Grouping as this code is not permitted to be used as a primary diagnosis</p>
VA Multiple Trauma	24	24	No change to HRG number or labels
VB Emergency Medicine	12	12	No change to HRG number or labels
VC Rehabilitation	23	23	No change to HRG number or labels
WD Treatment of Mental Health Patients by Non-Mental Health Service Providers	9	9	No change to HRG number or labels
WF Non-admitted Consultations	8	8	<p><u>Changes implemented in the HRG4+ 2021/22 Local Payment Grouper:</u></p> <p>The three new main specialty codes (MSC) introduced as part of the update to the DCB0028: Treatment Function and Main Specialty Standard, have been added to the Core 6 (outpatient) logic to ensure that these appropriately generate the default outpatient attendance HRGs within this subchapter.</p> <p>107 Vascular Surgery 200 Aviation and Space Medicine 317 Allergy</p>

Subchapter	LP21/22	LP20/21 v2 (July 2020)	Comment
WH Poisoning, Toxic Effects, Special Examinations, Screening and Other Healthcare Contacts	68	68	<p><u>Changes implemented in the HRG4+ 2021/22 Consultation Grouper:</u></p> <p>U07.3 Personal history of COVID-19 was remapped from HRG root WH15 Special Screening, Examinations or Other Genetic Disorders to UZ01 Data Invalid for Grouping as this code is not permitted to be used as a primary diagnosis</p> <p>U07.5 Multisystem inflammatory syndrome associated with COVID-19 was remapped from HRG root WH15 Special Screening, Examinations or Other Genetic Disorders to HRG root WJ06 Sepsis for adult patients</p> <p><u>Changes implemented in the HRG4+ 2021/22 Local Payment Grouper:</u></p> <p>U07.6 Need for immunization against COVID-19 has been remapped from HRG root WH15 Special Screening, Examinations or Other Genetic Disorders to WH19 Potential Health Hazard Related to Communicable Disease for adult patients only</p> <p>U07.7 COVID-19 vaccines causing adverse effects in therapeutic use has been remapped for adult patients from HRG root WH15 Special Screening, Examinations or Other Genetic Disorders to UZ01 Data Invalid for Grouping as this code is not permitted to be used as a primary diagnosis</p>
WJ Infectious Diseases and Immune System Disorders	38	38	<p><u>Changes implemented in the HRG4+ 2021/22 Consultation Grouper:</u></p> <p>U07.5 Multisystem inflammatory syndrome associated with COVID-19 was remapped from HRG root WH15 Special Screening, Examinations or Other Genetic Disorders to HRG root WJ06 Sepsis for adult patients</p> <p>U07.5 Multisystem inflammatory syndrome associated with COVID-19 was added to the complications and comorbidities list for this subchapter, WJ_CC</p>
XA Neonatal Critical Care	6	6	No change to HRG number or labels
XB Paediatric Critical Care	9	9	No change to HRG number or labels
XC Adult Critical Care	7	7	No change to HRG number or labels
XD High Cost Drugs	58	58	No change to HRG number or labels
YA Neurological Imaging Interventions	11	11	No change to HRG number or labels

Subchapter	LP21/22	LP20/21 v2 (July 2020)	Comment
YD Thoracic Imaging Interventions	5	5	No change to HRG number or labels
YF Gastrointestinal Imaging Interventions	8	8	No change to HRG number or labels
YG Hepatobiliary and Pancreatic Imaging Interventions	16	16	No change to HRG number or labels
YH Musculoskeletal Imaging Interventions	8	8	No change to HRG number or labels
YJ Breast Imaging Interventions	12	12	No change to HRG number or labels
YL Urological Imaging Interventions	8	8	No change to HRG number or labels
YQ Vascular Open Procedures and Disorders	60	60	No change to HRG number or labels
YR Vascular Imaging Interventions	58	58	No change to HRG number or labels

The Documentation Suite

Below is a list of the various documents which are available to download from the National Casemix Office website: <https://digital.nhs.uk/services/national-casemix-office/downloads-groupers-and-tools>.

This documentation suite provides a comprehensive resource intended to help users understand HRG design concepts and logic as well as use the Grouper.

- The **Casemix Companion** is a starting point and general reference guide for anyone interested in learning about the casemix classification system used by the NHS in England. This document provides an introduction to HRGs, groupers, HRG4+ design concepts and grouping logic, and it contains links to additional resources.
- The **Grouper User Manual** provides instructions on how to prepare and group data using the Grouper software application. Sample data with expected results is provided. This document is updated with every grouper release.
- The **Summary of Changes** document provides an overview of the main differences between the current grouper design and its relevant predecessor.
- The **Chapter Summaries** document provides an overview of the scope, composition and relevant grouping logic of individual HRG subchapters, and it highlights significant changes made in the latest HRG design.
- The **Code to Group Workbook** is an Excel workbook that embodies the casemix design. It provides details of the constituent elements that contribute to HRG grouping, and it contains reference data such as the ICD-10 and OPCS-4 codes utilised in the design, the procedure and diagnosis hierarchies pertinent to a specific design, and the Complication and Comorbidities (CC) lists for HRG subchapters. The workbook also includes information on Programme Budgeting Category (PBC) mapping as well as a comprehensive list of HRG codes and labels.